EXSPRESSION OF MDR-GENES AND MONORESISTANCE GENES IN NON-SMALL-CELL LUNG CANCER
Abstract
We studied the expression of multidrug resistance genes (MDR) and monoresistance genes in normal bronchial tissue and tumor tissue of the non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy (NACT) (vinorelbine-carboplatine). The study included 30 patients with NSCLC (Т2–4N0–3M0)). Normal bronchial tissue, normal lung tissue and tumor tissue collected during surgery following neoadjuvant chemotherapy (NACT) served as a material of the study. The expression levels of MDR genes (ABCB1, ABCB2, ABCC1, ABCC2, ABCС5, ABCG1, ABCG2, GSTP and MVP, and monoresistance genes (BRCA1, ERCC1, RRM1, TOP1, TOP2A, TUBB3 and TYMS) were estimated by quantitative reverse transcriptase PCR (RT-qPCR). The expression levels of some MDR genes and monoresistance genes (АВСВ1, АВСВ2, ABCG1, ERCC1, GSTP1 and MVP) were significantly higher in the bronchi than in tumor tissue. The expression of ABCG1, ABCG2 and ERCC1 genes was higher in patients with T1-2 cancer than in patients with T3-4 cancer. Patients with adenocarcinoma had higher expression of BRCA1, MVP and ABCB1 genes than patients with squamous cell lung cancer. A tendency towards reduction in the expression level of MDR-genes and monoresistance genes was observed in patients with partial tumor regression compared to that observed in patients with stable disease. These findings were consistent with the previous data on reduction in the MDR-gene expression after chemotherapy with a good response in breast cancer patients.
About the Authors
E. L. Yumov
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
М. М. Tsyganov
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
N. V. Litviakov
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
National Research Tomsk State University, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
T. V. Polishchuk
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
S. V. Miller
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Е. Родионов
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
S. A. Tuzikov
Cancer Research Institute of Siberian Вranch of the Russian Academy of Medical Sciences, Tomsk
Siberian State Medical University, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
References
1. Арсеньев А.И. Адъювантная xимиотерапия и лучевая терапия операбельного немелкоклеточного рака лёгкого // Практическая онкология. 2006. Т. 7, № 3. С. 154–160.
2. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013. 232 с
3. Литвяков Н.В., Гарбуков Е.Ю., Слонимская Е.М. и др. Связь безметастатической выживаемости больных раком молочной железы и вектора изменения экспрессии генов множественной лекарственной устойчивости в опухоли при проведении неоадъювантной химиотерапии // Вопросы онкологии. 2013. Т. 59, № 3. С. 334–340.
4. Литвяков Н.В. Градиентный феномен экспрессии генов множественной лекарственной устойчивости в опухоли молочной железы при проведении неоадъювантной химиотерапии: связь с прогрессированием заболевания // Сибирский онкологический журнал. 2013. № 4 (58). С. 5–11.
5. Миллер С.В., Тузиков С.А., Гольдберг В.Е. и др. Неоадъювантная химиотерапия таксанами в комбинированном лечении немелкоклеточного рака легкого // Российский онкологический журнал. 2011. № 5. С. 4–8.
6. Трахтенберг А.Х., Колбанов К.И. Рак легкого. М.: ГЭОТАР- Медиа, 2012. 160 с.
7. Butts C.A., Ding K., Seymour L. et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II nonsmall-cell lung cancer: updated survival analysis of JBR-10 // J. Clin. Oncol. 2009. Vol. 28. P. 29–34.
8. Ferlay J., Shin H.R., Bray F. et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; Year. Available at: http://globocan.iarc.fr. 2010.
9. Litviakov N.V., Cherdyntseva N.V., Tsyganov M.M. et al. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response // Cancer Chemother. Pharmacol. 2013. Vol. 71 (1). P. 153–163.
10. Olaussen K.A., Dunant A., Fouret P. et al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy // New Engl. J. Med. 2006. Vol. 355 (10). P. 983–991.
11. Porhanov V.A., Poliakov I.S., Kononenko V.B. et al. Surgery for Stage III A-B NSCLC (with mediastinal lymph nodes involvement) // J. Thorac. Oncol. 2007. Vol. 2 (8). S. 787.
12. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR // Nucleic Acids Res. 2001. Vol. 29. e. 45.
13. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview // Adv. Drug Deliv. Rev. 2003. Vol. 55 (1). P. 3–29.
14. Schettino C., Bareschino M.A., Maione P. et al. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer // Current genomics. 2008. Vol. 9 (4). P. 252–262.
15. Siegel R., Naishadham D., Jemal A. Cancer Statistics, 2012. // CA Cancer J. Clin. 2012. Vol. 62. P. 10–29.
16. Simon G.R., Ismail-Khan R., Bepler G. Nuclear excision repairbased personalized therapy for non-small cell lung cancer: from hypothesis to reality // Int. J. Biochem. Cell Biol. 2007. Vol. 39. P. 1318–1328.
17. Song W.A., Zhou N.K., Wang W. et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated metaanalysis of 13 randomized control trials //J. Thorac. Oncol. 2010. Vol. 5 (4). P. 510–516.
18. Su C., Zhou S., Zhang L. et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer // Med. Oncol. 2011. Vol. 28 (4). P. 1411–1417.
Review
For citations:
Yumov E.L., Tsyganov М.М., Litviakov N.V., Polishchuk T.V., Miller S.V., , Tuzikov S.A. EXSPRESSION OF MDR-GENES AND MONORESISTANCE GENES IN NON-SMALL-CELL LUNG CANCER. Siberian journal of oncology. 2014;(1):16-22. (In Russ.)
Views:
831
Email this article 
